Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study

15 Feb 2021

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Lung Cancer Treatments and Mutations
Share to Melanoma and MAPK Pathways

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 33587894
DOI: 10.1016/s1470-2045(20)30726-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation studyPMID 33587894Read ↗

Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma.Semantic proximity Read ↗

Circulating Tumor DNA: A Promising Biomarker for Predicting Recurrence in Patients with BRAF-Negative Melanoma.Semantic proximity Read ↗

Circulating tumor DNA is a prognostic biomarker in metastatic melanoma patients treated with chemoimmunotherapy and BRAF inhibitor.Semantic proximity Read ↗

In-depth assessment of BRAF, NRAS, KRAS, EGFR, and PIK3CA mutations on cell-free DNA in the blood of melanoma patients receiving immune checkpoint inhibitionSemantic proximity Read ↗

Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic MelanomaSemantic proximity Read ↗

Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients.Semantic proximity Read ↗

Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors.Semantic proximity Read ↗

Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNASemantic proximity Read ↗

Circulating Tumor DNA Is Prognostic of Patient Outcome and Enables Therapy Monitoring in Metastatic Uveal Melanoma.Semantic proximity Read ↗

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.Semantic proximity Read ↗

Monitoring Melanoma Using Circulating Free DNASemantic proximity Read ↗

Locus‐specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.